Immage Biotherapeutics Corp.
IMMG · OTC
2/28/2017 | 11/30/2016 | 8/31/2016 | 5/31/2016 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.00 | -0.00 | 0.00 |
| FCF Yield | -47,413.89% | -47,522.72% | -46,870,612.93% | -42,439.73% |
| EV / EBITDA | 1.28 | 0.09 | 2.38 | 5.47 |
| Quality | ||||
| ROIC | -197.35% | -696.03% | -25.83% | -20.40% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1,635.18 | 42.56 | 1,127.49 | 1,245.56 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -1.22% | -3.35% | -10.44% | -5.19% |
| Safety | ||||
| Net Debt / EBITDA | 1.28 | 0.09 | 2.38 | 5.47 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |